Takehiro Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takehiro Sato has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Hironori Waki
Department of Metabolism and Endocrinology Akita University Graduate School of Medicine Akita Japan
3 shared publications Sayaka Ando
Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
3 shared publicationsTatsunori Shimizu
Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
3 shared publicationsTsukasa Morii
Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
3 shared publications- Hiroki Fujita
Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
2 shared publications K. Kurashima
Advanced Materials Laboratory, National Institute for Materials Science, Namiki 1-1,#N#Tsukuba, Ibaraki 305-0044,#N#Japan
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0235
Metreleptin improves glucose metabolism and hepatic steatosis in a patient with Werner syndrome and partial lipodystrophy: a case report with review of literature
Werner syndrome (WS) is a rare autosomal recessive progeroid disorder caused by mutations in the WRN gene and is characterized by distinctive physical features and metabolic complications, including insulin resistance, diabetes, hypertriglyceridemia, and hepatic steatosis. Although lipodystrophy is a recognized component of WS, clinical reports of metreleptin use in this setting remain very limited. We report the case of a 38-year-old woman with WS complicated by partial lipodystrophy, diabetes with suboptimal glycemic levels, hypertriglyceridemia and severe hepatic steatosis. She presented with distal limb lipoatrophy, a bird-like facial appearance, premature hair graying, and cataracts. Genetic testing identified two pathogenic WRN variants (c.1105C>T and c.3446del) resulting in premature protein termination, confirming the diagnosis. At baseline, hemoglobin A1c (HbA1c) was 8.6% despite insulin and oral hypoglycemic agents, and imaging demonstrated hepatomegaly with marked steatosis. Metreleptin therapy was initiated and titrated. Over 26 weeks, HbA1c improved to 7.4% and the visceral-to-subcutaneous fat ratio decreased, accompanied by reduction in liver transaminases, cholestatic enzymes, and imaging-based indices of hepatic steatosis, liver stiffness, and liver volume. To date, only three cases of WS treated with metreleptin, including ours, have been reported. While glycemic improvement is consistent with prior reports, our case additionally demonstrated improvements in hepatic steatosis across biochemical, and imaging parameters. These findings suggest that metreleptin may improve both glucose metabolism and hepatic steatosis in WS-associated lipodystrophy. Further accumulation of cases is essential to clarify its role in the management of WS.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0235
Open AccessMetreleptin improves glucose metabolism and hepatic steatosis in a patient with Werner syndrome and partial lipodystrophy: a case report with review of literature
Werner syndrome (WS) is a rare autosomal recessive progeroid disorder caused by mutations in the WRN gene and is characterized by distinctive physical features and metabolic complications, including insulin resistance, diabetes, hypertriglyceridemia, and hepatic steatosis. Although lipodystrophy is a recognized component of WS, clinical reports of metreleptin use in this setting remain very limited. We report the case of a 38-year-old woman with WS complicated by partial lipodystrophy, diabetes with suboptimal glycemic levels, hypertriglyceridemia and severe hepatic steatosis. She presented with distal limb lipoatrophy, a bird-like facial appearance, premature hair graying, and cataracts. Genetic testing identified two pathogenic WRN variants (c.1105C>T and c.3446del) resulting in premature protein termination, confirming the diagnosis. At baseline, hemoglobin A1c (HbA1c) was 8.6% despite insulin and oral hypoglycemic agents, and imaging demonstrated hepatomegaly with marked steatosis. Metreleptin therapy was initiated and titrated. Over 26 weeks, HbA1c improved to 7.4% and the visceral-to-subcutaneous fat ratio decreased, accompanied by reduction in liver transaminases, cholestatic enzymes, and imaging-based indices of hepatic steatosis, liver stiffness, and liver volume. To date, only three cases of WS treated with metreleptin, including ours, have been reported. While glycemic improvement is consistent with prior reports, our case additionally demonstrated improvements in hepatic steatosis across biochemical, and imaging parameters. These findings suggest that metreleptin may improve both glucose metabolism and hepatic steatosis in WS-associated lipodystrophy. Further accumulation of cases is essential to clarify its role in the management of WS.
- Open Access
- 22 September 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 229, 112913
Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study
- 22 September 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 229, 112913
Open AccessImpact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study
- Open Access
- 1 January 2024
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 71 (4) , 409-416
Recurrent nocturnal hypoglycemic hemiplegia: a case report and review of the literature
A 67-year-old man with type 1 diabetes, Cronkhite-Canada syndrome, and membranous nephropathy who received insulin therapy was admitted to our hospital with right hemiplegia and dysarthria. Brain magnetic resonance imaging revealed a lesion with a high diffusion-weighted imaging signal and low apparent diffusion coefficient signal in the posterior limb of the left internal capsule. He was hypoglycemic with a blood glucose level of 56 mg/dL (3.1 mmol/L). Following glucose administration, the patient’s symptoms resolved within several hours. The patient experienced similar transient hypoglycemic hemiplegia at midnight, three times within 10 days. In a literature review of 170 cases of hypoglycemic hemiplegia, 26 cases of recurrent hemiplegia were investigated. Recurrent hypoglycemic hemiplegia occurs more frequently on the right side than on the left side, and most recurrences occur within approximately a week, almost exclusively at midnight and in the early morning. We speculate that hypoglycemia-associated autonomic failure may be involved in the nocturnal recurrence of episodes. In our patient, depleted endogenous insulin secretion and lipodystrophy at the injection site, may have acted as additional factors, leading to severe hypoglycemia despite the absence of apparent autonomic neuropathy. Clinically, it is important to recognize hypoglycemia as a cause of hemiplegia to avoid unnecessary intervention and to maintain an appropriate blood glucose level at midnight and early in the morning to prevent recurrent hypoglycemic hemiplegia.
- 1 January 2024
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 71 (4) , 409-416
Open AccessRecurrent nocturnal hypoglycemic hemiplegia: a case report and review of the literature
A 67-year-old man with type 1 diabetes, Cronkhite-Canada syndrome, and membranous nephropathy who received insulin therapy was admitted to our hospital with right hemiplegia and dysarthria. Brain magnetic resonance imaging revealed a lesion with a high diffusion-weighted imaging signal and low apparent diffusion coefficient signal in the posterior limb of the left internal capsule. He was hypoglycemic with a blood glucose level of 56 mg/dL (3.1 mmol/L). Following glucose administration, the patient’s symptoms resolved within several hours. The patient experienced similar transient hypoglycemic hemiplegia at midnight, three times within 10 days. In a literature review of 170 cases of hypoglycemic hemiplegia, 26 cases of recurrent hemiplegia were investigated. Recurrent hypoglycemic hemiplegia occurs more frequently on the right side than on the left side, and most recurrences occur within approximately a week, almost exclusively at midnight and in the early morning. We speculate that hypoglycemia-associated autonomic failure may be involved in the nocturnal recurrence of episodes. In our patient, depleted endogenous insulin secretion and lipodystrophy at the injection site, may have acted as additional factors, leading to severe hypoglycemia despite the absence of apparent autonomic neuropathy. Clinically, it is important to recognize hypoglycemia as a cause of hemiplegia to avoid unnecessary intervention and to maintain an appropriate blood glucose level at midnight and early in the morning to prevent recurrent hypoglycemic hemiplegia.
- 1 September 2001
- Published by Elsevier in Chemical Physics Letters
- Vol. 346 (1-2) , 29-34
C to BN conversion in multi-walled nanotubes as revealed by energy-filtering transmission electron microscopy
- 1 September 2001
- Published by Elsevier in Chemical Physics Letters
- Vol. 346 (1-2) , 29-34
C to BN conversion in multi-walled nanotubes as revealed by energy-filtering transmission electron microscopy
- 1 January 2000
- Published by Taylor & Francis in Philosophical Magazine A
- Vol. 80 (1) , 129-142
Co-produced carbon and boron nitride helical cones and the nucleation of curved BN sheets
The structure of carbon (C) and boron nitride (BN) columnar particles produced alongside by heat-treating a turbostratic B—C—N compound was investigated by analytical transmission electron microscopy. The particles were shown to be helical cones with a well-defined apex, and a helical pitch equal to usually one and at most two layers. The cone apex angle distribution was found to be centred on different values for C and BN. These results strongly suggested that BN and C cones nucleated from different ring defects in the hexagonal networks: square-like ring defects in BN and pentagon-like ring defects in C. These observations were consistent with the supposition that the creation of non B—N bonds and hence odd-membered rings is avoided in BN. Such restriction in BN could also allow one to understand the observed morphological differences between C and BN cones, and in particular the relative difficulty for BN cone edges to join via curved sheets.
- 1 January 2000
- Published by Taylor & Francis in Philosophical Magazine A
- Vol. 80 (1) , 129-142
Co-produced carbon and boron nitride helical cones and the nucleation of curved BN sheets
The structure of carbon (C) and boron nitride (BN) columnar particles produced alongside by heat-treating a turbostratic B—C—N compound was investigated by analytical transmission electron microscopy. The particles were shown to be helical cones with a well-defined apex, and a helical pitch equal to usually one and at most two layers. The cone apex angle distribution was found to be centred on different values for C and BN. These results strongly suggested that BN and C cones nucleated from different ring defects in the hexagonal networks: square-like ring defects in BN and pentagon-like ring defects in C. These observations were consistent with the supposition that the creation of non B—N bonds and hence odd-membered rings is avoided in BN. Such restriction in BN could also allow one to understand the observed morphological differences between C and BN cones, and in particular the relative difficulty for BN cone edges to join via curved sheets.